Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND:Extended-release niacin with laropiprant did not significantly reduce the risk of major vascular events and increased the risk of serious adverse events in Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE), but its net effects on health and healthcare costs are unknown. METHODS AND RESULTS:25 673 participants aged 50 to 80 years with previous cardiovascular disease were randomized to 2 g of extended-release niacin with 40 mg of laropiprant daily versus matching placebo, in addition to effective statin-based low-density lipoprotein cholesterol-lowering treatment. The net effects of niacin-laropiprant on quality-adjusted life years and hospital care costs (2012 UK £; converted into US $ using purchasing power parity index) during 4 years in HPS2-THRIVE were evaluated using estimates of the impact of serious adverse events on health-related quality of life and hospital care costs. During the study, participants assigned niacin-laropiprant experienced marginally but not statistically significantly lower survival (0.012 fewer years [standard error (SE) 0.007]), fewer quality-adjusted life years (0.023 [SE 0.007] fewer using UK EQ-5D scores; 0.020 [SE 0.006] fewer using US EQ-5D scores) and accrued greater hospital costs (UK £101 [SE £37]; US $145 [SE $53]). Stroke, heart failure, musculoskeletal events, gastrointestinal events, and infections were associated with significant decreases in health-related quality of life in both the year of the event and in subsequent years. All serious vascular and nonvascular events were associated with substantial increases in hospital care costs. CONCLUSIONS:In HPS2-THRIVE, the addition of extended-release niacin-laropiprant to statin-based therapy reduced quality of life-adjusted survival and increased hospital costs. CLINICAL TRIAL REGISTRATION:URL: Unique identifier: NCT00461630.

Original publication




Journal article


Circulation. Cardiovascular quality and outcomes

Publication Date





348 - 354


From the Health Economics Research Centre (S.K., A.G., B.M.) and Clinical Trial Service Unit and Epidemiological Studies Unit (R.H., J.C.H., S.P., M.J.L., R.C., J.A.), Nuffield Department of Population Health, University of Oxford, United Kingdom.


HPS2-THRIVE Collaborative Group, Humans, Cardiovascular Diseases, Niacin, Indoles, Lipids, Delayed-Action Preparations, Drug Combinations, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Treatment Outcome, Drug Therapy, Combination, Incidence, Risk Factors, Quality-Adjusted Life Years, Time Factors, Quality of Life, Aged, Aged, 80 and over, Middle Aged, Cost-Benefit Analysis, Drug Costs, Hospital Costs, China, Female, Male, Dyslipidemias, Hypolipidemic Agents, Scandinavian and Nordic Countries, Biomarkers, United Kingdom